Italy
Genespire is a promising player in the biotechnology sector, specializing in developing transformative gene therapies to tackle complex genetic diseases. The company primarily addresses primary immunodeficiencies and inherited metabolic diseases, aiming for durable solutions that significantly improve patient outcomes. This Milan-based company was founded in March 2020 by experts like Prof. Luigi Naldini and Dr. Alessio Cantore, along with entities like Fondazione Telethon and Ospedale San Raffaele.
As a spin-off from the renowned SR-Tiget, Genespire benefits from cutting-edge research in cell and gene therapy. Its potential was recently acknowledged in a substantial €46.60M Series B investment in September 2024, led by experienced investors including Sofinnova Partners, Indaco Venture Partners, XGEN Venture, and CDP Venture Capital. This fresh capital is expected to accelerate its research and development endeavors, solidifying its standing in the ever-evolving life sciences landscape.
